Company Filing History:
Years Active: 2012
Title: Richard Jonathan Daniel Hatley: Innovator in Xanthine Derivatives
Introduction
Richard Jonathan Daniel Hatley is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on xanthine derivatives. His research focuses on compounds that can selectively activate the HM74A receptor, which has implications for treating various diseases.
Latest Patents
Hatley's most recent patent is titled "Xanthine derivatives as selective HM74A agonists." This invention relates to a specific xanthine compound derivative, which is identified as 3-butyl-8-chloro-1-(3-{5-[(4-fluorophenyl)methyl]-2H-tetrazol-2-yl}propyl)-3,7-dihydro-1H-purine-2,6-dione. The patent also covers pharmaceutically acceptable salts, corresponding pharmaceutical formulations, combinations, preparation methods, and methods or uses in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor will be beneficial. Hatley holds 1 patent in this area.
Career Highlights
Hatley has built a career at GlaxoSmithKline LLC, a leading global healthcare company. His work has been instrumental in advancing the understanding and application of xanthine derivatives in medical treatments. His innovative approach has positioned him as a key figure in pharmaceutical research.
Collaborations
Throughout his career, Hatley has collaborated with several talented individuals, including Andrew McMurtrie Mason and Ivan Leo Pinto. These collaborations have enhanced the research and development of his patented inventions.
Conclusion
Richard Jonathan Daniel Hatley is a distinguished inventor whose work on xanthine derivatives has the potential to impact the treatment of various diseases. His contributions to the field of pharmaceuticals are noteworthy and reflect his commitment to innovation.